FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Authors:
Top Cited Papers
- 1 July 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (13) , 3753-3758
Abstract
The FDA approved pembrolizumab on May 23, 2017, for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H), or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options and for the treatment of unresectable or metastatic MSI-H or dMMR colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. The FDA granted the approval based on an understanding of the biology of MSI-H/dMMR across different tumors along with the clinically important effects on overall response rate (ORR) observed in patients who were enrolled in 1 of 5 single-arm clinical trials. The ORR was 39.6% among 149 patients with 15 different tumor types (95% confidence interval, 31.7–47.9), with a 7% complete response rate. The duration of response ranged from 1.6+ months to 22.7+ months, with 78% of responses lasting ≥6 months. Overall, the adverse event profile of pembrolizumab was similar to the adverse event profile observed across prior trials that supported the approval of pembrolizumab in other indications. This approval of pembrolizumab is the first time that the FDA has approved a cancer treatment for an indication based on a common biomarker rather than the primary site of origin.Keywords
Funding Information
- HHS | U.S. Food and Drug AdministrationHHS | U.S. Food and Drug Administration (FDA) (n/a)
This publication has 17 references indexed in Scilit:
- Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair DeficiencyJournal of Clinical Oncology, 2016
- Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung CancerThe Oncologist, 2016
- Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing PanelsJournal of Clinical Oncology, 2016
- Genomic correlates of response to CTLA-4 blockade in metastatic melanomaScience, 2015
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level AnalysesJournal of Clinical Oncology, 2015
- Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS StudiesClinical Cancer Research, 2014
- Challenges in the Identification of MSH6-Associated Colorectal CancerAmerican Journal of Surgical Pathology, 2011
- MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide ResistanceClinical Cancer Research, 2009